

REPUBLIC OF SOUTH AFRICA  
PATENTS ACT, 1978**PUBLICATION PARTICULARS AND ABSTRACT**

(Section 32(3)(a) – Regulation 22(1)(g) and 31)

OFFICIAL APPLICATION NO.

LODGING DATE

ACCEPTANCE DATE

21 01 **2002/1744**

22 1 MAR 2002

43 10-11-03

INTERNATIONAL CLASSIFICATION

NOT FOR PUBLICATION

51 A61K; A61P

CLASSIFIED BY: WIPO

FULL NAMES OF APPLICANT

71 PHARMACIA ITALIA SPA

FULL NAMES OF INVENTORS

72 1. MUGGETTI, LORENA  
2. COLOMBO, PAOLO  
3. MARTINI, ALESSANDRO  
4. BUZZI, GIOVANNI

EARLIEST PRIORITY CLAIMED

COUNTRY

NUMBER

DATE

33 GB

31 9921958.6

32 16 SEP 1999

TITLE OF INVENTION

54 FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE AND SULFOALKYL ETHER CYCLODEXTRINS

57 ABSTRACT (NOT MORE THAT 150 WORDS)

NUMBER OF SHEETS 22

If no classification is finished, Form P.9 should accompany this form.  
The figure of the drawing to which the abstract refers is attached.

## Abstract

A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustine phosphate to be administered with no side effects at the site of injection.

**FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE AND SULFOALKYL ETHER CYCLODEXTRINS**

5

The present invention relates to pharmaceutical formulations of estramustine phosphate for parenteral use and, more particularly, to formulations of estramustine phosphate for parenteral use further comprising sulfoalkyl ether cyclodextrins.

Estramustine phosphate (The Merck Index, XII Ed., No. 3749, 1996) is an estradiol-17 $\beta$ -phosphate derivative widely known in the art as antitumor agent, currently used in the treatment of advanced adenocarcinoma of the prostate.

The drug is usually administered orally, preferably at a dose of 10-15 mg/kg/day. Intravenous administration, however, is also adopted in some particular cases.

For example, initial intravenous administration of estramustine phosphate, followed by oral administration, has been reported at dosages paralleling the oral administration for the drug, i.e. 300-600 mg daily given intravenously and usually repetitively over for several consecutive days (see, for a reference, British Journal of Urology, 1977, 49, 73-79; J. Urol.108:303-306, 1972; Eur. Clin. Pharmacol. 26(1), 113-119, 1984; Eur. Urol. 1990, 17, 216-218).

Estramustine phosphate as well as other well-known cytotoxic compounds used in antitumor therapy are known to cause, or potentially cause, vascular damages at the site of injection when parenterally, in particular intravenously, administered.

As an example, studies in patients treated with estramustine phosphate administered as a slow intravenous injection or as a bolus, at 300 mg/day, revealed

thrombophlebitis and local irritations at the peripheral intravenous injection sites.

These drawbacks are considered major limitations for the intravenous administration of estramustine phosphate, thus requiring, in many patients, the establishment of central line administration or, in some cases, even discontinuation of the treatment.

With the aim of minimising the unwanted effects associated with the intravenous administration of cytotoxic agents, a few means are reported in the art.

Among them is the use of hydroxypropyl-cyclodextrin, in the preparation of formulations for parenteral administration of cytotoxic known to cause ulcerative lesions. See, for a reference, US patent No. 5,804,568 in the name of Supergen Inc.

Sulfoalkyl ether cyclodextrins are known in the art as solubilizing agents for insoluble or poorly soluble drugs (see, for a reference, US 5,134,127 in the name of the University of Kansas).

In this respect, we found formulations for parenteral use comprising estramustine phosphate together with sulfoalkyl ether cyclodextrins which, unexpectedly, resulted to achieve optimal protection from side-effects associated with estramustine administration.

It is therefore the object of the present invention a formulation for parenteral use comprising estramustine phosphate in admixture with a sulfoalkyl ether cyclodextrin.

Once administered intravenously to patients, the formulations object of the present invention do not provoke ulcerative damages, nor thrombophlebitis, at the site of injection.

In the present invention, unless otherwise specified, with the term formulation comprising estramustine phosphate, as

the active ingredient, we intend any formulation comprising estramustine phosphate either in the acid form or as a pharmaceutically acceptable salt for parenteral administration such as, for instance, a salt with a basic amino acid or with N-methyl glucamine, otherwise referred to as meglumine.

Preferably, estramustine phosphate is in the form of its meglumine salt.

10 With the term sulfoalkyl ether cyclodextrin we refer to any cyclodextrin of the above type wherein alkyl stands for straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl group such as methyl, ethyl, n.propyl, isopropyl, n.butyl, isobutyl, sec-butyl, tert-butyl, n.pentyl, n.hexyl and the like.

15 Preferably, the formulations of the present invention comprise estramustine phosphate in admixture with sulfoethyl ether  $\beta$ -cyclodextrin.

According to a preferred embodiment of the invention, the above formulations are advantageously used for intravenous use.

As such, these formulations of the invention can be administered to patients either as a slow injection, e.g. over about 30 minutes to about 3 hours, or as a bolus injection, also referred to as IV (intravenous) push.

Preferably, these formulations comprise estramustine phosphate in admixture with a sulfoalkyl ether cyclodextrin wherein the weight ratio between estramustine phosphate and sulfoalkyl ether cyclodextrin is from about 1:1 to about 1:5, respectively.

Formulations containing even higher amounts of sulfoalkyl ether cyclodextrin with respect to the active, are however still effective and thus comprised within the scope of the present invention.

In addition, it is herewith provided a very advantageous method for delivering estramustine phosphate intravenously, even when high doses of the active are needed.

It is therefore a further object of the invention a formulation for parenteral use comprising estramustine phosphate, as a single infusion dosage of the active exceeding 1300 mg, in admixture with a sulfoalkyl ether cyclodextrin.

According to another preferred embodiment of the invention, it is further provided a formulation for parenteral use comprising estramustine phosphate, as a single infusion dosage of the active exceeding 950 mg/m<sup>2</sup>, in admixture with a sulfoalkyl ether cyclodextrin.

In a yet further preferred embodiment, the estramustine phosphate is provided in lyophilised form and the sulfoalkyl ether cyclodextrin is provided in physiological solution. Formulations of this type may typically be presented as a kit.

The formulations object of the present invention allow the administration of the active either as a single agent or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, e.g. aromatase inhibitors, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), metallomatrixprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents, farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.

As an example, the above formulations can be administered in combination with one or more chemotherapeutic agents, optionally within liposomal formulations thereof.

5 Examples of chemotherapeutic agents are, for instance, taxane, taxane derivatives, CPT-11, camptothecin and derivatives thereof, anthracycline glycosides, e.g. doxorubicin, idarubicin or epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin and the like, optionally within liposomal formulations thereof.

10 In addition, the above formulations can be also administered in combination with protein kinase inhibitors such as, for instance, the indolinone derivatives disclosed by Sugen in the international patent applications WO 96/40116 and WO 99/61422, which are herewith incorporated  
15 by reference.

In this respect, the formulations object of the invention can be preferably administered in combination with 3-[4-(2-carboxyethyl-3,5-dimethylpyrrol-2-yl)methylidanyl]-2-indolinone and 3[(2,4-dimethylpyrrol-5-yl)methylidanyl]-2-  
20 indolinone, better known as Sugen SU 6668 and SU 5416, respectively.

The formulations of the invention may be administered sequentially with known anticancer agents when a combination formulation is inappropriate.

25

Therefore, it is a further object of the present invention a product containing a formulation for parenteral use of estramustine phosphate in admixture with a sulfoalkyl ether cyclodextrin and one or more chemotherapeutic agents, as a  
30 combined preparation for simultaneous, separate or sequential use in anticancer therapy.

### **Toxicology**

To study the local irritant effects of estramustine phosphate after repeated intravenous administrations to  
35 rats, in comparison to a formulation of estramustine phosphate according to the present invention, the active

was dissolved in different vehicles such as water solution for injection and water solution for injection further containing different amounts of sulfoalkyl ether cyclodextrin.

5 In particular, the following solutions of estramustine phosphate: sulfobutyl ether  $\beta$ -cyclodextrin in a weight ratio of 1:2 and of 1:4, respectively, were prepared and tested.

10 Male Sprague-Dawley rats were used because of their acceptance as a predictor of toxic change in man. The rats were 6 weeks old at the start of the study.

Estramustine phosphate, in the form of meglumine salt, was administered to groups of rats as a repeated intravenous injection during 3 days. Rats were then sacrificed: a half  
15 of the rats at the fourth day and a half at the fifth day.

The dose level of estramustine phosphate, in all the different tested solutions, was of 150 mg/kg/day.

Clinical observations were recorded daily. Thrombophlebitic side effects resulted in a dark bluish/blackish coloration  
20 of the tail during the treatment period.

A score system based on tail coloration and its extension was used to evaluate the different tested formulations.

The score system considered estramustine phosphate water solution as the positive control (i.e. marked toxicity).

25 Water for injection was administered to the control group as negative control (i.e. no toxicity signs).

Histological evaluation was carried out on the tail of the rats treated with the composition of the invention.

30 Estramustine phosphate in a water solution induced, at the used dose, local irritant effects at the injection site after the first administration and marked toxicity signs at the end of the experiment.

Sulfobutyl ether  $\beta$ -cyclodextrin containing formulations, according to the present invention, showed no toxicity  
35 signs even when this excipient was present at low concentrations. Histological evaluation of the tail of the rats treated with the formulations containing sulfobutyl

ether  $\beta$ -cyclodextrin did not reveal any damage when compared to the tails of the control group.

5 It was thus concluded that estramustine phosphate in a water solution containing sulfoalkyl ether cyclodextrin, according to the present invention, induced markedly less local irritant effects when compared with a water solution of the same.

10 One particularly preferred schedule for administering the formulation of estramustine phosphate according to the invention is a single infusion given once weekly to a maximal dose of 4000 mg or 3500 mg/m<sup>2</sup>.

Another preferred schedule is the administration of a  
15 single drug infusion once every two to four weeks.

One schedule may be preferred over another in consideration of schedules with other optional concomitant therapy. These schedules may repeat in serial or as repetitive fashion.

20 The formulations of the present invention are useful in antitumor therapy, particularly in the treatment of prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer and cancers of the brain.

25

The formulations object of the present invention are prepared according to conventional techniques adopted in the preparation of pharmaceutical forms for parenteral use. Typically, a proper amount of estramustine phosphate,  
30 either as a dry powder or into a lyophilised form, is dissolved in a pharmaceutically acceptable solution for parenteral use and then admixed with a proper amount of a sulfoalkyl ether cyclodextrin, for instance sulfobutyl ether  $\beta$ -cyclodextrin.

35 As an example, a proper amount of estramustine phosphate in the form of a suitable salt such as, for instance, N-methyl glucamine salt, is dissolved in a suitable amount of

sterile water or aqueous dextrose solution, e.g. 5% dextrose in water for intravenous administration, and then admixed with a proper amount of powdered sulfobutyl ether  $\beta$ -cyclodextrin.

5 The above admixture is then stirred, sterilised, and subsequently lyophilised according to conventional techniques.

The freeze-dried formulation is prepared and stored in vials for injection; the addition of a proper amount of  
10 sterile water or a physiological solution for parenteral use enables the preparation of the final formulation to be injected.

Alternatively, the final formulation to be injected may be prepared by reconstituting the freeze-dried formulation  
15 comprising the active principle with a proper amount of sterile water or of a physiological solution for parenteral use already containing a proper amount of a sulfoalkyl ether cyclodextrin.

The above method is also suitable for preparing high  
20 dosages estramustine phosphate formulations whilst maintaining the desired weight ratio between the components.

The unit strength of the formulation to be injected depended on the concentration of the active in the solution  
25 itself and, of course, on the filling volume of the vials used to prepare the final formulation.

Additionally, the formulations of the present invention may optionally contain pharmaceutically acceptable excipients  
30 for parenteral administration such as, for instance, bulking agents, e.g. lactose or mannitol, pH buffering agents, anti-oxidant agents, preservative agents, tonicity adjusters and the like.

35 The following examples are herewith intended to better illustrate the present invention without representing any limitation to it.

**Example 1****Preparation of estramustine phosphate:sulfobutyl ether  $\beta$ -cyclodextrin=1:4.2 weight ratio**

5 300 mg of estramustine phosphate were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. 120.8 mg of N-methyl-glucamine were then added under stirring to the watery dispersion of the active and, after a few minutes, a clear solution was obtained. 1250 mg of  
10 sulfobutyl ether  $\beta$ -cyclodextrin were added, maintaining the solution under stirring until complete dissolution.

The obtained solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate and 125 mg/ml of  
15 sulfobutyl ether  $\beta$ -cyclodextrin (1:4.2 weight ratio - 1:1 molar ratio respectively).

A solution prepared as previously described, properly sterilized by filtration, was tested for its local vein tolerability in rats.

20

**Example 2**

The formulation described in Example 1 was also prepared by solubilization of the commercially available Estracyt<sup>®</sup> freeze-dried formulation containing 300 mg/vial of the  
25 active. The reconstitution of the formulation was made using 10 ml of a 125 mg/ml sulfobutyl ether  $\beta$ -cyclodextrin solution so as to obtain a final concentration of 30 mg/ml of estramustine phosphate and 125 mg/ml of cyclodextrin (1:4.2 weight ratio - 1:1 molar ratio respectively).

30

**Example 3****Preparation of estramustine phosphate:sulfobutyl ether  $\beta$ -cyclodextrin=1:2.1 weight ratio**

35 300 mg of estramustine phosphate were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. 120.8 mg of N-methyl-glucamine were then added under stirring to the watery dispersion of the active and, after a few minutes, a clear solution was obtained. 625 mg of

sulfobutyl ether  $\beta$ -cyclodextrin were added, maintaining the solution under stirring until complete dissolution.

The obtained solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 5 30 mg/ml of estramustine phosphate and 62.5 mg/ml of sulfobutyl ether  $\beta$ -cyclodextrin (1:2.1 weight ratio - 1:0.5 molar ratio respectively).

A solution prepared as previously described, properly sterilized by filtration, was tested for its local vein 10 tolerability in rats.

#### Example 4

The formulation described in Example 3 was also prepared by solubilization of the commercially available Estracyt® 15 freeze-dried formulation containing 300 mg/vial of the active. The reconstitution of the formulation was made using 10 ml of a 62.5 mg/ml sulfobutyl ether  $\beta$ -cyclodextrin solution so as to obtain a final concentration of 30 mg/ml of estramustine phosphate and 62.5 mg/ml of cyclodextrin 20 (1:2.1 weight ratio - 1:0.5 molar ratio respectively).

**CLAIMS**

1. A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent and estramustine phosphate and a sulfoalkyl ether cyclodextrin.  
5
2. A formulation according to claim 1 wherein the weight ratio of estramustine phosphate to the sulfoalkyl ether cyclodextrin is from about 1:1 to about 1:5.  
10
3. A formulation according to claim 1 or 2 which is in single infusion dosage form comprising at least 1300 mg of the estramustine phosphate.  
15
4. A formulation according to any one of the preceding claims which is in single infusion dosage form comprising at least 950 mg/m<sup>2</sup> of the estramustine phosphate.  
20
5. A formulation according to any one of the preceding claims wherein the sulfoalkyl ether cyclodextrin is a straight or branched C<sub>1</sub>-C<sub>6</sub> sulfoalkyl ether cyclodextrin.  
25
6. A formulation according to claim 5 wherein the sulfoalkyl ether cyclodextrin is sulfobutyl ether β-cyclodextrin.
- 30 7. A formulation according to any one of the preceding claims for intravenous use.
8. A formulation according to any one of the preceding claims wherein the estramustine phosphate is in the form of a pharmaceutically acceptable salt for intravenous use.  
35

9. A formulation according to claim 8 wherein the estramustine phosphate is in the form of N-methyl glucamine salt.
- 5 10. A formulation according to any one of the preceding claim for use in the treatment of cancer.
11. A formulation as claimed in claim 10 wherein the cancer is prostate cancer, breast cancer, melanoma, lung  
10 cancer, pancreatic cancer, colorectal cancer, ovarian cancers or cancer of the brain.
12. A formulation according to claim 1 wherein the parenterally acceptable carrier is a physiological  
15 solution for parenteral use which contains the sulfoalkyl ether cyclodextrin, and the estramustine phosphate is in lyophilised form.
13. A formulation according to claim 1 wherein the  
20 estramustine phosphate is in admixture with the sulfoalkyl ether cyclodextrin.
14. A product which comprises  
(i) a pharmaceutical formulation which comprises a  
25 parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin, and  
(ii) one or more chemotherapeutic agents;  
as a combined preparation for simultaneous, separate or  
30 sequential use in anticancer therapy.
15. A product according to claim 14 wherein the sulfoalkyl ether cyclodextrin is sulfobutyl ether  $\beta$ -cyclodextrin.
- 35 16. A product according to claim 14 or 15 wherein the chemotherapeutic agent, optionally encapsulated within

liposomes, is selected from taxane, taxane derivatives, CPT-11, camptothecin and derivatives thereof, doxorubicin, idarubicin or epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin, Sugem  
5 SU 6668 and Sugem SU 5416.

17. A product according to claim 14 for intravenous use.
18. A product according to claim 14 for use in the  
10 treatment of prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer or cancer of the brain.
19. A formulation as defined in claim 7 for use in  
15 suppressing or reducing the side-effects associated with the intravenous administration of estramustine phosphate and pharmaceutically acceptable salts thereof.
20. A formulation according to claim 19 wherein the side  
20 effects comprise ulcerative lesions and thrombophlebitis at the site of injection.
21. A product which comprises estramustine phosphate in  
25 lyophilised form and a physiological solution for parenteral use containing a sulfoalkyl ether cyclodextrin.
22. Use, in the manufacture of a medicament for parenteral  
30 administration, of estramustine phosphate and a sulfoalkyl ether cyclodextrin.
23. Use according to claim 22 wherein the medicament is for  
intravenous administration.